Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.32 |
| ▸ | CBX7 | O95931 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13918705 | 0.93 | MAPT (0.35) | LMNAMAPTKMT2ATDP1MEN1 | |
| SCHEMBL1573088 | 0.91 | RARB (0.34) | LMNAMAPTKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL4496071 | 0.91 | KMT2A (0.38) | LMNAMAPTKMT2ATDP1MEN1 | |
| SCHEMBL1573145 | 0.91 | RARB (0.34) | LMNAMAPTKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL1573301 | 0.91 | KMT2A (0.38) | LMNAMAPTKMT2ATDP1MEN1 | |
| SCHEMBL1573188 | 0.88 | ALDH1A1 (0.35) | LMNAMAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL1572736 | 0.87 | KMT2A (0.35) | LMNAMAPTKMT2ATDP1MEN1 | |
| SCHEMBL4503731 | 0.85 | MAPT (0.34) | LMNAMAPTKMT2ATDP1MEN1 | |
| SCHEMBL1573232 | 0.84 | ALDH1A1 (0.33) | LMNAMAPTKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL4516628 | 0.84 | KDM4E (0.37) | LMNAMAPTKMT2ATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | LMNA 3360/4885MAPT 3588/4885KMT2A 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.